Faster* and greater* drying with fewer injections vs. aflibercept1-3
Flexible dosing and extended durability1,2,4
Powerful dual-pathway
inhibition5-8
*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO.
References
- Khanani AM, et al. Ophthalmology. 2024;19:S0161-6420(24)00134-9.
- Wong TY, et al. Ophthalmology. 2024;131(6):708-723.
- Chaudhary V, et al. Presented at ARVO 2023.
- Tadayoni R, et al. Presented at Angiogenesis 2024, presentation available at medically.roche.com.
- Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
- Heier JS, et al. Lancet. 2022;399:729–40.
- Wykoff CC, et al. Lancet. 2022;399:741–55.
- VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024.
M-PK-00002048